Philogen owns two CMC manufacturing sites in the vicinity of Siena: Monteriggioni and Rosia.
The site of Monteriggioni has been certified GMP since 2004 and is designed to produce small batches of biopharmaceuticals for clinical trials. The facility is equipped with two 30L stainless steel stirred bioreactors for mammalian cell fermentation and a 450m2 classified area for drug manufacturing. A stand-alone viral safety facility is also available.
A new CMC manufacturing unit of 1,100m2 is being completed in Rosia with an expected start of activities in the near future. It will be equipped with two fully independent manufacturing lines with 150L scale bioreactors. The site of Rosia already hosts Philogen's headquarters, administration and clinical operations offices.